FDA reviewers highlight risks for AstraZeneca’s Onglyza
According to a preliminary review of data by US Food and Drug Administration reviewers, Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) Onglyza (saxagliptin), a treatment for type 2 diabetes, may pose health risks.
Last year, the FDA requested clinical trial data from AstraZeneca to investigate a possible association between use of saxagliptin and heart failure (The Pharma Letter February 12, 2014).
The FDA's report on Friday comes ahead of an April 14 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss the safety of Onglyza, and Nesina (alogliptin) and Oseni (alogliptin and pioglitazone), similar drugs from Japan’s Takeda Pharmaceutical. Onglyza gained US marketing approval in 2009 and Nesina in 2013. Sales of Onglyza increased by 119% to $820 million for full-year 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze